UGT2B7-mediated drug–drug interaction between cannabinoids and hydromorphone
Drug Metabolism and Disposition · 2025-09 · 53 (9) · 100135
DOI: 10.1016/j.dmd.2025.100135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025-09. Verfasst von Shelby Coates und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Hydromorphone, Cannabinoids, Analgesics, Opioid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, State of Washington, Washington State University.
Abstract (Originalsprache)
Hydromorphone is a highly potent opioid used to treat severe chronic pain. It is metabolized primarily by UDP-glucuronosyltransferase (UGT)2B7 to form the inactive hydromorphone-3-glucuronide. Given that previous studies have shown that the major cannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), inhibit several UGT enzymes, the objective of the present study was to determine the inhibitory potential of major cannabinoids and their metabolites on UGT-mediated hydromorphone metabolism. To evaluate the potential for cannabis-induced drug interactions, cannabinoids and their metabolites were screened as potential inhibitors against hydromorphone glucuronidation in pooled human liver microsomes and microsomes from cells overexpressing recombinant UGT2B7. IC50 values were determined for cannabinoids that inhibited hydromorphone glucuronidation by 50% and Ki values for those that exhibited an IC50 1.25-fold increase in hydromorphone exposure), with physiologically based pharmacokinetic predictive models indicating that CBD would cause a 20%-30% increase in hydromorphone exposure in healthy and cirrhotic individuals. These data suggest that major cannabinoids such as CBD will cause moderate drug-drug interactions with hydromorphone in humans. SIGNIFICANCE STATEMENT: This study indicates that major cannabinoids and their metabolites found in the plasma of cannabis users inhibit UGT2B7-mediated hydromorphone metabolism in vitro. It further demonstrates the potential for in vivo inhibition of hydromorphone metabolism by cannabinoids and their metabolites, indicating the potential for drug-drug interactions upon concomitant use of hydromorphone and cannabis or hydromorphone together with individual cannabinoids like Δ9-tetrahydrocannabinol and cannabidiol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
- Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Division of Molecular Biosciences, Department of Pharmaceutical Sciences, School…
- Division of Molecular Biosciences, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York.
Förderung
- NIDA NIH HHS
- State of Washington
- Washington State University
- National Institute on Drug Abuse
Zitieren
APA
Coates, S., Bardhi, K., Zhao, M., & Lazarus, P. (2025). UGT2B7-mediated drug–drug interaction between cannabinoids and hydromorphone. Drug Metabolism and Disposition, 53(9), 100135. https://doi.org/10.1016/j.dmd.2025.100135
Vancouver
Coates S, Bardhi K, Zhao M, Lazarus P. UGT2B7-mediated drug–drug interaction between cannabinoids and hydromorphone. Drug Metabolism and Disposition. 2025;53(9):100135. doi:10.1016/j.dmd.2025.100135
BibTeX
@article{Coates2025,
author = {Coates, Shelby and Bardhi, Keti and Zhao, Mengqi and Lazarus, Philip},
title = {UGT2B7-mediated drug–drug interaction between cannabinoids and hydromorphone},
journal = {Drug Metabolism and Disposition},
year = {2025},
volume = {53},
number = {9},
pages = {100135},
doi = {10.1016/j.dmd.2025.100135}
}
EUVIMED